2Mahaffey KW, Held C, Wojdyla DM. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the platelet inhibition and patient outcomes (PLATO)trial. J Am Coil Cardiol, 2014, 63:1493-1499.
3Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associatied with antibodies specific for ligand-occupied GP II b/III a. Blood, 2002, 100:2071-2076.
4Huxtable LM, Tafreshi M J, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein l[ b/III a receptor antagonists. Am J Cardiol, 2006, 97:426-429.
5Tuhta AG, Yesildag O, K6priilii D. Tirofiban-associated acute thrombocytopenia. Acta Cardiol, 2006, 61:577-579.
3Dasgupta H, Blankenship JC, Wood GC, et al. Thrombocytopenia complicating treatment with intravenous glycoprotein Ⅱb/Ⅲa receptor inhibitors: a pooled analysis. Am Heart J, 2000,140: 206-211.
4Huxtable LM, Tafreshi M J, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprolein Ⅱb/Ⅲa receplor antagonists. Am J Cardiol, 2006,97:426-429.
5Razakjr OA, Tan HC, Yip WL, et al. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention. J Interv Cardiol, 2005,18:33-37.
6The RESTORE Investigators. Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997, 96: 1445-1453.
7Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable sign and symptoms ( PRISM-PLUS ) study investigators. Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl Med, 1998,338 : 1488-1497,
8Berkowitz SD, Sane DC, Sigmon KN ,et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization, Evaluation of c7E3 for the Prevention of Ischemic Complications ( EPIC ) Sludy Group. J Am Coll Cardiol,1998,32:311-319.
9Bougie DW, Wilker PR, Wuitschick ED, et. al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associatied with antibodies sepectific for ligand-occupied GP Ⅱb/Ⅲa. Blood, 2002,100:2071-2076.
10Patel S, Patel M, Din I, et al. Profound thrombocytopenia associated with tirofiban : case report and review of literature. Angiology, 2005,56:351-355.
6Said SM, Hahn J, Schleyer E, et al. Glycoprotein Ⅱb/Ⅲa inhibitor-induced thrombocytopenia: diagnosis and treatment. Clin Res Cardiol, 2007, 96:61-69.
7Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein Ⅱb/Ⅲa inhibitors. Curr Hematol Rep, 2004,3 : 143-147.
8Huynh T,Piazza N, DiBattiste PM, et al. Analysis of bleeding complications associated with glycoprotein Ⅱb/Ⅲa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study. Int J Cardiol, 2005,100: 73-78.
